Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Papp

Showing results (371-380 of 406) with videos related to

Pageof 41
Sort By:
Dermatology and Therapy|April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
The New England Journal of Medicine|July 16, 2020
Trial of Roflumilast Cream for Chronic Plaque PsoriasisMark G Lebwohl, Kim A Papp, Linda Stein Gold, et al.
Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
The Journal of Investigative Dermatology|August 16, 2025
Comparative molecular analysis of IL-17A and IL-23 pathway inhibition in moderate-to-severe psoriasis: 4-week results from IXORA-RSandra Garcet, Lam C Tsoi, Hong Hur, et al.
Archives of Dermatological Research|June 8, 2024
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registryKim A Papp, Melinda Gooderham, Charles Lynde, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
Journal of Cutaneous Medicine and Surgery|August 12, 2023
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Pageof 41

Showing results (371-380 of 406) with videos related to

Sort By:
Pageof 41
Dermatology and Therapy|April 21, 2022
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Jennifer Beecker, Curtis Cooper, et al.
The New England Journal of Medicine|July 16, 2020
Trial of Roflumilast Cream for Chronic Plaque PsoriasisMark G Lebwohl, Kim A Papp, Linda Stein Gold, et al.
Dermatology and Therapy|March 17, 2023
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert PanelKim A Papp, Barbara Melosky, Sandeep Sehdev, et al.
The Journal of Investigative Dermatology|August 16, 2025
Comparative molecular analysis of IL-17A and IL-23 pathway inhibition in moderate-to-severe psoriasis: 4-week results from IXORA-RSandra Garcet, Lam C Tsoi, Hong Hur, et al.
Archives of Dermatological Research|June 8, 2024
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registryKim A Papp, Melinda Gooderham, Charles Lynde, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.
The British Journal of Dermatology|February 26, 2016
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasisK A Papp, K Reich, C Paul, et al.
Journal of Cutaneous Medicine and Surgery|August 12, 2023
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Pageof 41